PubMed Health⌕ Search

PubMed · 7116284

Agoraphobia.

Abstract

The authors focus on the nature of agoraphobia and on treatments for it. A variety of myths about agoraphobia are examined such as those concerning the patient's childhood, sexual development, and marital history, and the conclusion is that none of these helps in understanding the nature of the condition. The recent notion that agoraphobia is merely a form of endogenous depression is refuted. Of the four traditional languages of psychiatry, the medical and behavioural models are currently more in vogue than the genetic or psychoanalytic, but there are limitations in all models. It is shown why the behavioural therapies for agoraphobia may not be as universally helpful as implied by the recent research literature. The apparent success of both pharmacotherapy and behaviour therapy leaves models of agoraphobia which are at variance with each other, and the authors suggest possible lines of research which might resolve the contradiction.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M S Rapp, M R Thomas. 1982. Agoraphobia.. https://doi.org/10.1177/070674378202700512

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Linkage genome scan for loci predisposing to panic disorder or agoraphobia.

We conducted a 10 cM linkage genome scan in a set of 20 American pedigrees (153 subjects), ascertained through probands with panic disorder (PD). Several anxiety disorders segregate in these families; they were diagnosed on the basis of Schedule for Affective Disorders and Schizophrenia interview. In this article, we describe results for panic disorder and agoraphobia, which are closely related, common, heritable anxiety disorders. This is the first complete linkage genome scan for agoraphobia and the third for PD. A total of 407 markers (389 autosomal, 18 X chromosome) were genotyped. Multipoint LOD score and NPL analysis were completed using GENEHUNTER2. For PD, two genomic regions meet criteria for suggestive linkage. One of these regions is on chromosome 1 (LOD score = 2.04). This region coincides with a region that generated a LOD score of 1.1 in a previous genome scan by Crowe et al. [2001: Am J Med Genet (Neuropsychiatr Genet) 105:105-109]. The other (LOD score = 2.01) is located on chromosome 11p and occurs at marker CCKBR, one of eight candidate genes examined. For agoraphobia, the most promising potential linkage was on chromosome 3 (NPL score = 2.75; P = 0.005). This was accounted for primarily by a single family that by itself generated an NPL score of 10.01 (P = 0.0039) and a LOD score of 2.10. These results provide initial evidence for a genetic locus on chromosome 3 that contributes to risk for agoraphobia. They also support suggestive linkage to two risk loci for panic disorder. Additional potential loci were identified with lesser statistical support; several of these were consistent with previously reported panic disorder linkage results. Overall, the results presented here suggest that PD and agoraphobia are complex traits that share some, but not all, of their susceptibility loci. Published 2001 Wiley-Liss, Inc.

Agoraphobia↗

[Current drug treatment. Effects of antidepressive agents in nervous and stress-related disorders].

Antidepressants have a much broader range of indication than the name suggests. The efficacy of antidepressant treatment of nervous and stress-related disorders has been documented in several controlled trials, both in comparison with placebo and with other antidepressants. Most studies have included testing in panic disorder, with or without agoraphobia, and obsessive compulsive disorder, but there is empirical evidence for the efficacy of the drugs in most anxiety disorders. Antidepressants with a preference for serotonergic neurotransmission (i.e. clomipramine and SSRIs (serotonin specific reuptake inhibitors) are particularly effective in the treatment of panic disorder and obsessive compulsive disorder. Owing to their more favourable side effect profile as compared with classical antidepressants, the SSRIs are considered to be the drugs of first choice, except for generalised anxiety disorder, where the efficacy of venlafaxine has been most thoroughly documented. Studies comparing different antidepressant are warranted. So are studies elucidating the relative benefits of drug treatment and psychotherapy, but, with the concept of modern anxiety treatment, there is no principal objection to combining the two treatment methods.

Agoraphobia↗